Presentation at ENDO 2024 — “Diabetes Stem Cells: A Common Target for Abnormal Insulin Secretion and Insulin Resistance”

June 2024 — At ENDO 2024, the annual meeting of the Endocrine Society and one of the world’s leading gatherings of endocrinology experts, our research team presented a scientific poster entitled “Diabetes Stem Cells: A Common Target for Abnormal Insulin Secretion and Insulin Resistance.” This year’s meeting attracted thousands of scientists, clinicians, and industry leaders from over 100 countries, making it an unparalleled platform to introduce new research addressing the global diabetes crisis.

Our poster presentation highlighted the role of Diabetes Stem Cells (DSCs) as a central driver of both impaired insulin secretion and insulin resistance. Traditional approaches to diabetes management have focused primarily on the pancreas and peripheral tissues, often treating symptoms rather than causes. By identifying DSCs as the underlying source of metabolic dysfunction, our research suggests a unifying mechanism that connects the two major pathological features of diabetes. This finding provides a new conceptual framework for developing therapies that address the disease at its root rather than simply controlling blood glucose levels.

The presentation also introduced advances in therapeutic strategies designed to eliminate or “reset” these abnormal cells. In particular, we emphasized the potential of HDAC inhibitors combined with insulin therapy to restore normal stem cell function, as well as the integration of Biozipcode™ drug delivery technology, which enables highly targeted treatment with minimal side effects. This approach builds on more than two decades of basic and translational research and aligns with ongoing international clinical efforts to demonstrate complete remission of diabetes in human trials.

Participation in ENDO 2024 underscored the importance of sharing emerging scientific insights with the global endocrinology community. The discussions that followed our presentation highlighted broad interest in moving beyond glucose management to genuine disease-modifying therapies. We are grateful to the organizers of ENDO 2024 for providing this platform and to the many researchers, clinicians, and industry partners who engaged with our work. As the fight against diabetes continues, our team remains committed to advancing research and innovation that can transform diabetes from a lifelong condition into a curable disease.